Zanamivir for the prevention of influenza in adults and children age 5 years and older.

Article Details

Citation

Copy to clipboard

Eiland LS, Eiland EH

Zanamivir for the prevention of influenza in adults and children age 5 years and older.

Ther Clin Risk Manag. 2007 Jun;3(3):461-5.

PubMed ID

18488077 [ View in PubMed

]

Abstract

On a yearly basis there are 3-5 million severe cases and 250,000-500,000 deaths worldwide attributed to influenza. Four antiviral medications are currently available on the market; however, resistance has resulted in the armamentarium being shrunk to two remaining active treatment options for influenza. These two neuraminidase inhibitors, oseltamivir and zanamivir, are recommended for the treatment and prophylaxis of influenza A and B in children and adults. Zanamivir, which is the focus of this review, is an inhaled antiviral that has shown benefit in the community, household, and nursing home population for post-exposure prophylaxis. Zanamivir protection rates range from 67%-84% in clinical trials of adults and children. Although the influenza vaccine remains the best modality to combat the disease, zanamivir may also assist in decreasing morbidity associated with influenza A and B.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Zanamivir	Neuraminidase	Protein	Influenza B virus (strain B/Beijing/1/1987)	Yes	Inhibitor	Details